MARKET

ZGNX

ZGNX

Zogenix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.49
-0.23
-1.46%
After Hours: 15.50 +0.01 +0.06% 18:34 09/24 EDT
OPEN
15.63
PREV CLOSE
15.72
HIGH
16.03
LOW
15.48
VOLUME
357.66K
TURNOVER
--
52 WEEK HIGH
23.69
52 WEEK LOW
13.01
MARKET CAP
865.86M
P/E (TTM)
-3.5253
1D
5D
1M
3M
1Y
5Y
Zogenix (ZGNX) Moves 6.2% Higher: Will This Strength Last?
Zacks.com · 2d ago
Zogenix Reports Granting of Inducement Awards
Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company's board of directors granted inducement awards to fourteen (14) new employees. The awards were made on September 15, 2021, under Zogenix's 2021 Employment Inducement Equi...
GlobeNewswire · 09/16 21:39
UBS Initiates Coverage On Zogenix with Buy Rating, Announces Price Target of $23
UBS analyst Esther Rajavelu initiates coverage on Zogenix (NASDAQ:ZGNX) with a Buy rating and announces Price Target of $23.
Benzinga · 09/09 12:11
University Of Oxford-Sponsored Study Titled 'Fenfluramine and Cognition (FEN&Cognition)' Posted To ClinicalTrials.Gov; Study Is Recruiting
https://clinicaltrials.gov/ct2/show/NCT05026398
Benzinga · 08/30 16:33
Return on Capital Employed Insights for Zogenix
After pulling data from Benzinga Pro it seems like during Q2, Zogenix (NASDAQ:ZGNX) brought in sales totaling $18.79 million. However, earnings decreased 7.0%, resulting in a loss of $55.43 million.
Benzinga · 08/30 15:09
BRIEF-Zogenix Receives Orphan Drug Designation For Fintepla In Japan
reuters.com · 08/26 13:45
Zogenix Receives Orphan Drug Designation For FINTEPLA In Japan
Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the Japanese Ministry of Health, Labour & Welfare (MHLW) has granted Orphan Drug Designation to
Benzinga · 08/26 12:01
Zogenix Receives Orphan Drug Designation for FINTEPLA(R) (Fenfluramine) in Japan
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the Japanese Ministry of Health, Labour & Welfare (MHLW) has granted Orphan Drug Designation to FINTEPLA(R) (fenfluramine) oral solution, whi...
GlobeNewswire · 08/26 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZGNX. Analyze the recent business situations of Zogenix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZGNX stock price target is 41.00 with a high estimate of 62.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 246
Institutional Holdings: 70.44M
% Owned: 126.01%
Shares Outstanding: 55.90M
TypeInstitutionsShares
Increased
53
3.43M
New
16
3.46M
Decreased
50
6.68M
Sold Out
24
1.37M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Cam Garner
President/Chief Executive Officer/Director
Stephen Farr
Chief Financial Officer/Executive Vice President/Treasurer/Secretary
Michael Smith
Executive Vice President/General Counsel/Secretary
Shawnte Mitchell
Executive Vice President
Gail Farfel
Executive Vice President
Bradley Galer
Executive Vice President
Ashish Sagrolikar
Independent Director
Louis Bock
Independent Director
James Breitmeyer
Independent Director
Caroline Loewy
Independent Director
Erle Mast
Independent Director
Mary Stutts
Independent Director
Renee Tannenbaum
Independent Director
Denelle Waynick
Independent Director
Mark Wiggins
No Data
About ZGNX
Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.

Webull offers kinds of Zogenix, Inc. stock information, including NASDAQ:ZGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZGNX stock methods without spending real money on the virtual paper trading platform.